Skip to content

Comparison of Two Screening Strategies for Gestational Diabetes (GDM2)

Comparison of Two Screening Strategies for Gestational Diabetes (GDM2)

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02309138
Acronym
GDM2
Enrollment
921
Registered
2014-12-05
Start date
2015-08-11
Completion date
2020-06-05
Last updated
2020-07-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gestational Diabetes, Glucose Intolerance, Pregnancy

Keywords

gestational diabetes screening, Carpenter Coustan Criteria, IADPSG criteria, Large for gestational age birth weight

Brief summary

This is a single site blinded RCT of 920 pregnant women with singleton gestation designed to compare the Carpenter-Coustan and IADPSG criteria for diagnosing gestational diabetes. Maternal metabolic profiles and infant growth will be assessed at randomization and at one year postpartum.

Detailed description

Impaired glucose metabolism (gestational diabetes (GDM) and mild hyperglycemia) that occurs during pregnancy is associated with an increased risk for pregnancy complications and is also an early indication of long-term metabolic dysfunction leading to diabetes and cardiovascular disease. In the US, GDM is diagnosed using a two-step screening and diagnostic approach. The International Association of Diabetes and Pregnancy Study Group (IADPSG) proposed a one-step diagnostic approach that broadens the definition of GDM by lowering the cutoff values to include women with milder forms of hyperglycemia, who would have screened normal under the current two-step approach. The goal of these recommendations is better identification of women at risk for pregnancy complications and long-term metabolic dysfunction, but it results in a significant increase in the prevalence of GDM. The NIH GDM Consensus Development Conference committee does not recommend changing from the current two-step screening/diagnostic approach to the IADPSG one-step diagnostic approach without trials demonstrating that increasing the number of women diagnosed as having GDM results in better outcomes. We aim to 1) conduct a real world randomized controlled trial (RCT) to determine differences in short-term perinatal health outcomes between the two predominant GDM screening approaches, and 2) prospectively follow the mothers to examine their metabolic risk profiles and the growth of their infants at 1 year postpartum. Based on a pilot study, we propose a single site blinded RCT of 920 pregnant women ages 18-45 years without a diagnosis of diabetes, with a singleton pregnancy (18-24 wks gestation). Participants will have a non-fasting 1 hour 50 gm glucose challenge test (GCT) performed between 24-28 weeks' gestation. Women with 50 gm GCT results \< 200 mg/dL will be randomized to receive either a fasting 2 hour 75 gm oral glucose tolerance test (OGTT) or a 3 hour 100 gm OGTT. GDM will be diagnosed using the IADPSG criteria for women receiving the 75 gm OGTT and Carpenter-Coustan criteria for women receiving the 100 gm. Participants and their physicians will be informed of the diagnosis of GDM, but blinded to the specific test results and diagnostic criteria. Participants with GDM will receive treatment from their primary provider. Questionnaires will be used to assess participants' and physicians' views on GDM testing. Metabolic profiles will be assessed at randomization and at a year postpartum. The primary outcome measure is large-for-gestational age fetal growth. The rationale for this RCT is that this is a unique opportunity to compare the two methods. At the end of the study, we will know whether women diagnosed at lower glucose levels with the IADPSG criteria are more likely to have adverse perinatal outcomes. We hypothesize that using IADPSG diagnostic criteria will result in greater detection of women with impaired glucose metabolism and treating these women will reduce adverse perinatal outcomes and prevent long-term metabolic dysfunction. This study will provide level A data for endorsing universal screening guidelines for GDM by major organizations and implementation into clinical care.

Interventions

DIAGNOSTIC_TESTGestational diabetes screening with fasting 3 hour 100 gm

Participants receive fasting 3 hour 100 gm oral glucose tolerance test

DIAGNOSTIC_TESTGestational diabetes screening with fasting 2 hour 75g

Participants receive fasting 2 hour 75 gm oral glucose tolerance test

Sponsors

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
CollaboratorNIH
Esa M Davis, MD MPH FAAFP
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SCREENING
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 45 Years
Healthy volunteers
Yes

Inclusion criteria

* Pregnancy between 18-24 weeks of gestation * Singleton gestation * Planning to deliver at Magee-Womens Hospital, Pittsburgh, Pennsylvania

Exclusion criteria

* Preexisting type 1 or 2 diabetes * Diabetes diagnosed at less than 24 weeks gestational age (GA) * Multiple gestations ( e.g. twins or triplets) * Hypertension requiring medications * Corticosteroid (IM, oral or IV) use in the 30 days prior to enrollment * Major congenital anomaly with anticipated preterm delivery due to maternal or fetal indications \< 28 wks GA * Inability to complete the glucose testing before 30 completed weeks GA * Advanced HIV( on medications that cause hyperglycemia), severe liver disease, gastric bypass surgery or other illness/surgeries that preclude them from drinking the glucola solution.

Design outcomes

Primary

MeasureTime frameDescription
Large for Gestational Age (LGA) Infantat time of deliverybirth weight equal to or greater than the 90th percentile for gestational age and sex

Secondary

MeasureTime frameDescription
Cesarean Deliveryat delivery (approximately 40 weeks' gestation)the delivery of a baby through a surgical incision in the mother's abdomen and uterus
Maternal Composite Morbidityat delivery (approximately 40 weeks' gestation)maternal pre-eclampsia, 3rd or 4th degree vaginal lacerations, post-partum hemorrhage
Neonatal Composite Morbidity7 days after birth1\) hypoglycemia: blood glucose \< 40mg/dl); 2) hyperbilirubinemia requiring treatment, clinical jaundice; 3)hyperinsulinemia- measured with c peptide level from venous cord blood; 4) still birth- absence of fetal heart tones before delivery, 5) birth trauma= Shoulder dystocia/brachial plexus injuries.

Countries

United States

Participant flow

Recruitment details

Pregnant women were recruited from June 2015 to February 2019 from 10 obstetrical clinics affiliated with Magee Women's Hospital in Pittsburgh,Pennsylvania

Participants by arm

ArmCount
3 Hour 100 gm OGTT (CC Criteria)
Gestational diabetes screening with fasting 3 hour 100 gm. Receive a fasting 3 hour 100 gram oral glucose tolerance test and are diagnosed based on the Carpenter Coustan Criteria: a 50 gm Glucose tolerance test of \>130 + fasting 3 hour 100 gram oral glucose tolerance test with two or more values greater than the following diagnostic threshold: Fasting 95, 1-hour 180, 2-hour 155, or 3 hour 140 mg/dL . A positive criteria will be diagnostic for gestational diabetes. Gestational diabetes screening with fasting 3 hour 100 gm: Participants receive fasting 3 hour 100 gm oral glucose tolerance test
460
2 hr 75 gm OGTT (IADPSG Criteria)
Gestational diabetes screening with fasting 2 hour 75g. Receive a fasting 2 hour 75 gm oral glucose tolerance test and diagnosed based on the IADPSG which is if one or more values exceed the following diagnostic threshold: Fasting 92, 1-hour 180, or 2-hour 153 mg/dL. Gestational diabetes screening with fasting 2 hour 75g: Participants receive fasting 2 hour 75 gm oral glucose tolerance test
461
Total921

Withdrawals & dropouts

PeriodReasonFG000FG001
Overall Studydelivered before visit 201
Overall StudyProtocol Violation42
Overall StudyWithdrawal by Subject4415

Baseline characteristics

CharacteristicTotal3 Hour 100 gm OGTT (CC Criteria)2 hr 75 gm OGTT (IADPSG Criteria)
Age, Continuous28.7 years
STANDARD_DEVIATION 5.2
28.8 years
STANDARD_DEVIATION 5.1
28.6 years
STANDARD_DEVIATION 5.3
Ethnicity (NIH/OMB)
Hispanic or Latino
30 Participants15 Participants15 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
888 Participants443 Participants445 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
3 Participants2 Participants1 Participants
First degree family history of diabetes200 Participants97 Participants103 Participants
Glucose Challenge 50 gm test106.2 mg/dl
STANDARD_DEVIATION 28.3
104.7 mg/dl
STANDARD_DEVIATION 27.7
107.8 mg/dl
STANDARD_DEVIATION 28.9
pre-pregnancy BMI26.8 kg/m2
STANDARD_DEVIATION 7
26.6 kg/m2
STANDARD_DEVIATION 6.8
26.9 kg/m2
STANDARD_DEVIATION 7.2
previous history of gestational diabetes22 Participants8 Participants14 Participants
Race (NIH/OMB)
American Indian or Alaska Native
1 Participants1 Participants0 Participants
Race (NIH/OMB)
Asian
27 Participants9 Participants18 Participants
Race (NIH/OMB)
Black or African American
300 Participants161 Participants139 Participants
Race (NIH/OMB)
More than one race
53 Participants26 Participants27 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
2 Participants0 Participants2 Participants
Race (NIH/OMB)
Unknown or Not Reported
28 Participants14 Participants14 Participants
Race (NIH/OMB)
White
510 Participants249 Participants261 Participants
Sex: Female, Male
Female
921 Participants460 Participants461 Participants
Sex: Female, Male
Male
0 Participants0 Participants0 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 4600 / 461
other
Total, other adverse events
154 / 46056 / 461
serious
Total, serious adverse events
17 / 4602 / 461

Outcome results

Primary

Large for Gestational Age (LGA) Infant

birth weight equal to or greater than the 90th percentile for gestational age and sex

Time frame: at time of delivery

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Overall IADPSG ArmLarge for Gestational Age (LGA) Infant34 Participants
Overall Carpenter CoustanLarge for Gestational Age (LGA) Infant35 Participants
IADPSG With no GDMLarge for Gestational Age (LGA) Infant28 Participants
Carpenter Coustan With no GDMLarge for Gestational Age (LGA) Infant34 Participants
Comparison: Co-primary hypotheses #1: women diagnosed using the IADPSG criteria will have lower rates of large-for-gestational age infants compared to those diagnosed using the Carpenter-Coustan criteria.p-value: 0.66897.5% CI: [0.538, 1.516]Regression, Logistic
Comparison: Co-primary hypothesis #2: women classified as no gestational diabetes by the IADPSG criteria will have lower rates of large-for-gestational age infants compared to those classified in the Carpenter-Coustan criteria.p-value: 0.85397.5% CI: [0.493, 1.475]Regression, Logistic
Secondary

Cesarean Delivery

the delivery of a baby through a surgical incision in the mother's abdomen and uterus

Time frame: at delivery (approximately 40 weeks' gestation)

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Overall IADPSG ArmCesarean Delivery131 Participants
Overall Carpenter CoustanCesarean Delivery118 Participants
IADPSG With no GDMCesarean Delivery101 Participants
Carpenter Coustan With no GDMCesarean Delivery101 Participants
p-value: 0.666995% CI: [0.847, 1.291]Regression, Logistic
p-value: 0.839495% CI: [0.816, 1.307]Regression, Logistic
Secondary

Maternal Composite Morbidity

maternal pre-eclampsia, 3rd or 4th degree vaginal lacerations, post-partum hemorrhage

Time frame: at delivery (approximately 40 weeks' gestation)

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Overall IADPSG ArmMaternal Composite Morbidity77 Participants
Overall Carpenter CoustanMaternal Composite Morbidity75 Participants
IADPSG With no GDMMaternal Composite Morbidity62 Participants
Carpenter Coustan With no GDMMaternal Composite Morbidity63 Participants
p-value: 0.933595% CI: [0.74, 1.318]Regression, Logistic
p-value: 0.92695% CI: [0.742, 1.407]Regression, Logistic
Secondary

Neonatal Composite Morbidity

1\) hypoglycemia: blood glucose \< 40mg/dl); 2) hyperbilirubinemia requiring treatment, clinical jaundice; 3)hyperinsulinemia- measured with c peptide level from venous cord blood; 4) still birth- absence of fetal heart tones before delivery, 5) birth trauma= Shoulder dystocia/brachial plexus injuries.

Time frame: 7 days after birth

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Overall IADPSG ArmNeonatal Composite Morbidity83 Participants
Overall Carpenter CoustanNeonatal Composite Morbidity57 Participants
IADPSG With no GDMNeonatal Composite Morbidity57 Participants
Carpenter Coustan With no GDMNeonatal Composite Morbidity48 Participants
p-value: 0.032295% CI: [1.027, 1.909]Regression, Logistic
p-value: 0.264395% CI: [0.864, 1.76]Regression, Logistic

Source: ClinicalTrials.gov · Data processed: Feb 15, 2026